Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

Recruiting now · Not applicable

Conditions studied: Ductal Breast Carcinoma in Situ

In brief

The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)

Key facts

Study ID

NCT03909282

Run by

Stanford University

People needed

50

Starts

2019-03-22

Expected to finish

2026-12-01

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality
• Signed and dated IRB-approved written informed consent
• Women 18 years of age or older
• Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease
• Estrogen receptor positive or negative, progesterone receptor positive, negative or unknown; HER2 positive, negative or unknown DCIS is allowed
• Diagnostic needle biopsy within 16 weeks of randomization
• Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging.
• Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible.
• Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization
• Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields
• Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible
• ECOG performance status 0, 1, or 2
• Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed

You may not qualify if…

• Invasive carcinoma on core needle biopsy, including microinvasive carcinoma
• Radiographic extent of DCIS >4.0 cm
• Mass lesion on breast imaging or palpable tumor
• No residual radiographic lesion after diagnostic percutaneous core needle biopsy
• Prior history of ipsilateral invasive or noninvasive breast cancer
• Pregnant or breastfeeding
• Prior ipsilateral breast or chest irradiation
• Multicentric or multifocal DCIS, if extent is > 4cm
• Synchronous contralateral invasive or noninvasive breast cancer
• Pagets' disease of the breast
• Active collagen vascular disease
• Positive axillary lymph nodes
• Not meeting the described criteria for partial breast irradiation during initial clinical evaluation.
• Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results
• Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer

Where it is running

• Stanford University — Stanford, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.